1-20 of 35
Michael J. Wick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A080: Establishment and characterization of a panel of prostate cancer XPDX models with differential AR-V7 staining and enzalutamide response

Jim Lund, Johnnie Flores, Alyssa Simonson, Armand Diaz III, Jared Knol, Naveen Kella, Drew Rasco, Kyriakos P Papadopoulos, Mark Campbell, Michael J Wick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A080.
https://doi.org/10.1158/1535-7163.TARG-23-A080
Published: 01 December 2023
View articletitled, Abstract A080: Establishment and characterization of a panel of prostate cancer XPDX models with differential AR-V7 staining and enzalutamide response
Journal Articles

Abstract C099: Establishment and characterization of an NUP98-KDM5A-driven AML XPDX model

Armando Diaz III, Alyssa Simonson, Johnnie Flores, Joseph Holahan, Kyriakos P Papadopoulos, Jim Lund, Drew Rasco, Amita Patnaik, Michael J Wick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C099.
https://doi.org/10.1158/1535-7163.TARG-23-C099
Published: 01 December 2023
View articletitled, Abstract C099: Establishment and characterization of an NUP98-KDM5A-driven AML XPDX model
Journal Articles

Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer

Craig Furman, Xiaoling Puyang, Zhaojie Zhang, Zhenhua J. Wu, Deepti Banka, Kiran B. Aithal, Lee A. Albacker, Ming-Hong Hao, Sean Irwin, Amy Kim, Meagan Montesion, Alyssa D. Moriarty, Karthikeyan Murugesan, Tuong-Vi Nguyen, Victoria Rimkunas, Tarek Sahmoud, Michael J. Wick, Shihua Yao, Xun Zhang, Hao Zeng, Frédéric H. Vaillancourt, David M. Bolduc, Nicholas Larsen, Guo Zhu Zheng, Sudeep Prajapati, Ping Zhu, Manav Korpal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 890–902.
https://doi.org/10.1158/1535-7163.MCT-21-0378
Published: 01 June 2022
View articletitled, Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer
Open the PDF for Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A011: Preclinical models of breast cancer brain metastasis for drug efficacy studies

Carsten H. Nielsen, Michael J. Wick, Lotte K. Kristensen, Henriette S. Joergensen, Maria Z. Alfsen, Mark U. Juul, Alyssa Moriarty, Kyriakos P. Papadopoulos, Andreas Kjaer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A011.
https://doi.org/10.1158/1535-7163.TARG-19-A011
Published: 01 December 2019
View articletitled, Abstract A011: Preclinical models of breast cancer brain metastasis for drug efficacy studies
Journal Articles

Abstract A008: PDX-based screen to evaluate and compare approved CDK4/6 inhibitors in breast cancer and determine palbociclib efficacy in additional tumor types

Lizette Gamez, Tomoyuki Mashimo, Alyssa Moriarty, Kyriakos Papadopoulos, Drew Rasco, Amita Patnaik, Amy Lang, Ronald Drengler, Lon Smith, Michael J Wick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A008.
https://doi.org/10.1158/1535-7163.TARG-19-A008
Published: 01 December 2019
View articletitled, Abstract A008: PDX-based screen to evaluate and compare approved CDK4/6 inhibitors in breast cancer and determine palbociclib efficacy in additional tumor types
Journal Articles

Abstract A017: Development and characterization of HER2+ T-DM1-resistant breast PDX models in athymic nude mice

Alyssa Moriarty, Lizette Gamez, Tomoyuki Mashimo, Kyriakos Papadopoulos, Amita Patnaik, Drew Rasco, Amy Lang, Ronald Drengler, Michael J Wick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A017.
https://doi.org/10.1158/1535-7163.TARG-19-A017
Published: 01 December 2019
View articletitled, Abstract A017: Development and characterization of HER2+ T-DM1-resistant breast PDX models in athymic nude mice
Journal Articles

Abstract A007: Establishment and characterization of the MDA-MB-175 breast tumor xenograft model

Michael J. Wick, Megan Groves, Alyssa Moriarty, Marcus Guerra, Melissa Rundle, Drew Rasco, Amita Patnaik, Anthony W. Tolcher, Kyriakos P. Papadopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A007.
https://doi.org/10.1158/1535-7163.TARG-17-A007
Published: 01 January 2018
View articletitled, Abstract A007: Establishment and characterization of the MDA-MB-175 breast tumor xenograft model
Journal Articles

Abstract A210: Evaluation and comparison of the CDK 4/6 inhibitor palbociclib in a panel of PDX models representing hormone-positive and -negative breast cancer

Alyssa Moriarty, Amanda Mangold, Ileana Munoz, Megan Groves, Marcus Guerra, Melissa Rundle, Kyriakos P. Papadopoulos, Drew Rasco, Anthony W. Tolcher, Amita Patnaik, Michael J. Wick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A210.
https://doi.org/10.1158/1535-7163.TARG-17-A210
Published: 01 January 2018
View articletitled, Abstract A210: Evaluation and comparison of the CDK 4/6 inhibitor palbociclib in a panel of PDX models representing hormone-positive and -negative breast cancer
Journal Articles

Abstract B169: Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2

Emiliano Cocco, F. Javier Carmona, Helen H. Won, Michael F. Berger, David M. Hyman, Valentina Rossi, Carmen Chan, Alyssa Moriarty, Kyriakos P. Papadopoulos, Michael J. Wick, James Cownie, Ivana Sarotto, Richard E. Cutler, Francesca Avogadri-Connors, Peter Savas, Alshad S. Lalani, Valentina Boni, Sherene Loi, Jose Baselga, Filippo Montemurro, Maurizio Scaltriti
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B169.
https://doi.org/10.1158/1535-7163.TARG-17-B169
Published: 01 January 2018
View articletitled, Abstract B169: Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
Journal Articles

Abstract A138: Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates

Krista Kinneer, John Meekin, Sandrina Phipps, Binyam Bezabeh, Ryan Fleming, Christine Kiefer, Marlon Rebelatto, Nazzareno Dimasi, Michael J. Wick, Alyssa Moriarty, Megan Groves, Ronald Herbst, Arnaud Tiberghien, Luke Masterson, Philip Howard, David Tice
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A138.
https://doi.org/10.1158/1535-7163.TARG-17-A138
Published: 01 January 2018
View articletitled, Abstract A138: Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates
Journal Articles

Abstract A011: HER2-positive PDX model of breast cancer brain metastasis obtained from patient prior to T-DM1 therapy

Carsten H. Nielsen, Michael J. Wick, Lizette Gamez, Camilla S. Knudsen, Mette M. Jense, Melissa Rundle, Kyriakos P. Papadopoulos, Andreas Kjaer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A011.
https://doi.org/10.1158/1535-7163.TARG-17-A011
Published: 01 January 2018
View articletitled, Abstract A011: HER2-positive PDX model of breast cancer brain metastasis obtained from patient prior to T-DM1 therapy
Journal Articles

Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

Ursula A. Germann, Brinley F. Furey, William Markland, Russell R. Hoover, Alex M. Aronov, Jeffrey J. Roix, Michael Hale, Diane M. Boucher, David A. Sorrell, Gabriel Martinez-Botella, Matthew Fitzgibbon, Paul Shapiro, Michael J. Wick, Ramin Samadani, Kathryn Meshaw, Anna Groover, Gary DeCrescenzo, Mark Namchuk, Caroline M. Emery, Saurabh Saha, Dean J. Welsch
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (11): 2351–2363.
https://doi.org/10.1158/1535-7163.MCT-17-0456
Published: 01 November 2017
View articletitled, Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Open the PDF for Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib) in another window
Includes: Supplementary data
Journal Articles

Abstract A15: Efficacy of trastuzumab emtansine (T-DM1) in subcutaneous and intracranial patient derived xenograft models of breast cancer metastasis

Carsten H. Nielsen, Mette K. Nedergaard, Lotte K. Kristensen, Camilla S. Knudsen, Michael J. Wick, Kyri Papadopoulos, Anthony W. Tolcher, Andreas Kjaer
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A15.
https://doi.org/10.1158/1535-7163.TARG-15-A15
Published: 01 December 2015
View articletitled, Abstract A15: Efficacy of trastuzumab emtansine (T-DM1) in subcutaneous and intracranial patient derived xenograft models of breast cancer metastasis
Journal Articles

Abstract B183: Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751

Sudharshan Eathiraj, Brian Schwartz, Yi Yu, Michael J. Wick, Terence Hall, Feng Chai, Jasgit Sachdev, Giovanni Abbadessa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B183.
https://doi.org/10.1158/1535-7163.TARG-15-B183
Published: 01 December 2015
View articletitled, Abstract B183: Targeting PI3K pathway dependent endometrial tumors with allosteric AKT inhibitors, ARQ 092 and ARQ 751
Journal Articles

Abstract B181: Association of AKT1E17K and PIK3CAH1047R mutations with efficacy of ARQ 092 in vitro, in vivo and in patients

Giovanni Abbadessa, Yi Yu, Sudharshan Eathiraj, Justin Meade, Michael J. Wick, Anthony Tolcher, Kyri Papadopoulos, Mansoor Saleh, Jasgit Sachdev, Feng Chai, Brian Schwartz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B181.
https://doi.org/10.1158/1535-7163.TARG-15-B181
Published: 01 December 2015
View articletitled, Abstract B181: Association of AKT1E17K and PIK3CAH1047R mutations with efficacy of ARQ 092 in vitro, in vivo and in patients
Journal Articles

Abstract B185: ARQ 092 enhances the efficacy of paclitaxel, lapatinib, trastuzumab, trametinib, and ARQ 087 both in cancer cell lines and mouse xenograft cancer models

Yi Yu, Justin Meade, Michael J. Wick, Hall Terence, Sudhi Eathiraj, Brian Schwartz, Giovanni Abbadessa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B185.
https://doi.org/10.1158/1535-7163.TARG-15-B185
Published: 01 December 2015
View articletitled, Abstract B185: ARQ 092 enhances the efficacy of paclitaxel, lapatinib, trastuzumab, trametinib, and ARQ 087 both in cancer cell lines and mouse xenograft cancer models
Journal Articles

Abstract C74: Establishment and characterization of a HER2-positive, TDM1-resistant PDX breast model

Michael J. Wick, Teresa L. Vaught, Justin Meade, Monica Farley, Armando Diaz, Anthony W. Tolcher, Drew W. Rasco, Amita Patnaik, Murali Beeram, Kyriakos P. Papadopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C74.
https://doi.org/10.1158/1535-7163.TARG-15-C74
Published: 01 December 2015
View articletitled, Abstract C74: Establishment and characterization of a HER2-positive, TDM1-resistant PDX breast model
Journal Articles

Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model

Colin J. Meyer, Melissa Krauth, Michael J. Wick, Jerry W. Shay, Ginelle Gellert, Jef K. De Brabander, Peter T. Northcote, John H. Miller
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (8): 1816–1823.
https://doi.org/10.1158/1535-7163.MCT-15-0167
Published: 05 August 2015
View articletitled, Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model
Open the PDF for Peloruside A Inhibits Growth of Human Lung and Breast Tumor Xenografts in an Athymic nu/nu Mouse Model in another window
Journal Articles

Abstract A13: Establishment and characterization of a panel of melanoma patient-derived xenograft (PDX) models.

Lizette Gamez, Michael J. Wick, Teresa L. Vaught, Monica Farley, Anthony W. Tolcher, Drew Rasco, Amita Patnaik, Alex Miller, Ron Drengler, Kyriakos P. Papadopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A13.
https://doi.org/10.1158/1535-7163.TARG-13-A13
Published: 01 November 2013
View articletitled, Abstract A13: Establishment and characterization of a panel of melanoma patient-derived xenograft (PDX) models.
Journal Articles

Abstract A105: Establishment, characterization and clinical correlation of a panel of gynecologic patient-derived xenograft (PDX) models.

Michael J. Wick, Abbey Felder, Alyssa Moriarty, Teresa L. Vaught, Anthony W. Tolcher, Drew Rasco, Amita Patnaik, Allen J. White, James Mark, Kyriakos P. Papadopoulos
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A105.
https://doi.org/10.1158/1535-7163.TARG-13-A105
Published: 01 November 2013
View articletitled, Abstract A105: Establishment, characterization and clinical correlation of a panel of gynecologic patient-derived xenograft (PDX) models.